Meeting
2021 ASCO Annual Meeting
Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.
Authors
Bailey Gleason Fitzgerald
The Tisch Cancer Institute at Mount Sinai Health System, New York, NY
Bailey Gleason Fitzgerald , Thomas Urban Marron , Dana Ostrowski , Jonah Shulman , Matko Kalac , Netonia Marshall , Joshua Brody
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT03305445
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2593)
DOI
10.1200/JCO.2021.39.15_suppl.2593
Abstract #
2593
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
First Author: Boyu Hu
Poster
2024 ASCO Annual Meeting
Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.
First Author: Biao Zheng
Poster
2021 ASCO Annual Meeting
KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
First Author: Saad Z. Usmani
Poster
2018 ASCO Annual Meeting
ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
First Author: Olalekan O. Oluwole